Comparative Pharmacology
Head-to-head clinical analysis: BENTYL versus PATHILON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENTYL versus PATHILON.
BENTYL vs PATHILON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dicyclomine is a muscarinic acetylcholine receptor antagonist that blocks the action of acetylcholine at postganglionic parasympathetic effector sites, reducing gastrointestinal smooth muscle spasms and hypermotility.
Anticholinergic agent that competitively inhibits muscarinic acetylcholine receptors, decreasing gastrointestinal motility and gastric acid secretion.
20 mg orally four times daily; may increase to 40 mg four times daily if tolerated. Immediate-release: 20 mg orally every 6 hours. Extended-release: 20 mg orally twice daily.
1-2 mg orally every 4-6 hours; maximum 12 mg/day. Alternatively, IM: 1-2 mg every 4-6 hours.
None Documented
None Documented
1.9 to 3 hours (terminal elimination half-life); clinical context: short half-life supports multiple daily dosing for spasm relief.
Terminal elimination half-life approximately 2-4 hours; may be prolonged in elderly or patients with hepatic/renal impairment.
Primarily renal (approximately 60% as unchanged drug and metabolites) and fecal (about 40% via biliary elimination).
Primarily renal (50-70% as unchanged drug and metabolites); biliary/fecal (20-30%); minor metabolism via hepatic ester hydrolysis.
Category C
Category C
Anticholinergic
Anticholinergic